ReposiTrak is a profitable food-safety software network that just posted its first down quarter after a long growth streak, and the pause arrived in the same window that management began pouring cash and credit into SPAR Group, a merchandising-services company later dropped from Nasdaq. The Food and Drug Administration pushed enforcement of the Food Safety Modernization Act Section 204 traceability rule out to mid-2028, stripping the near-term regulatory cliff that had been pulling suppliers onto the ReposiTrak Traceability Network. The investment debate is no longer whether the subscription conversion worked. It is whether a high-margin compounder still grows once the deadline recedes, and whether the SPAR stake is a platform extension or a capital-allocation error.
For the quarter ended in late March, revenue was essentially unchanged at just under $6 million. Operating income still rose as expenses fell, which is the signature of a converted subscription base rather than a business that has lost pricing power. Cash ended the period at $26 million after the SPAR loan and ongoing buybacks, with no bank debt. The equity closed at $8.19 on the publication date, less than half the prior-year peak, implying investors have already written off the enforcement cliff.
The coming year resolves two questions that decide whether this is still a growth equity or a high-margin stub. Does retailer-driven onboarding restart without a federal deadline, and does the SPAR relationship produce measurable software revenue rather than more equity and notes? Full-year results for the June fiscal close have not yet been published, so the March print remains the last complete operating picture.